Uniseed Investee Christophe Demaison advances COVID-19 preventative therapy through AU$32Million Fund Raise uniseed.com/uniseed-invest…

Great animation produced by SquareCell and @andylilja to explain the MOA of INNA-051, the broad spectrum innate modulator Christophe Demaison is developing for the prevention of COVID and other respiratory viruses #COVID youtube.com/watch?v=dbtkkj…

ENA Respiratory featured in ENDPOINTS NEWS Endpoints News in an article by Nicole DeFeudis endpts.com/australian-spi… #COVID19

ENA Respiratory featured in FiercePharma following the AU$32m capital raise announcement. fiercepharma.com/drug-delivery/…

The Currus Biologics team is thrilled to announce $10m investment from brandon capital and UniseedFund towards improving the success of CAR-T cell therapies against the treatment of solid tumours such as breast, ovarian and pancreatic cancers. afr.com/companies/heal…

ENA Respiratory starts Phase 1 trial for its broad spectrum antiviral nasal spray. fiercepharma.com/drug-delivery/…. #covid19solutions Christophe Demaison

We are delighted to be supporting Christophe Demaison with a Phase 2a Influenza human challenge study. Learn more below: globenewswire.com/news-release/2… #ChallengeStudies #hvivo

Christophe Demaison announce initiation of COVID-19 Post-Exposure Prophylaxis Phase 2 study in partnership with PPD and Phase 2a human influenza-challenge study in collaboration with hVIVO Learn more: globenewswire.com/news-release/2…

Great article by Anju Ghangurde in the recent Scrip, Citeline Commercial edition featuring ENA Respiratory and its upcoming Phase 2 studies in COVID and influenza. scrip.pharmaintelligence.informa.com/SC145202/Austr…

Delighted to have @brianwiley721 joining ENA Respiratory as Strategic Advisor to lead the Business Development activities of the company.

Last individual in INNA-051 Phase 1 was dosed this week. Over 75 individuals participated in this study that established the safety of Christophe Demaison's pan-antiviral nasal spray. With the emergence of omicron, at-risk populations need complementary approaches to vaccines.

We are thrilled to partner with the COPD Foundation to develop INNA-051 in people with chronic lung diseases. Read more about our partnership here: globenewswire.com/news-release/2… #COPD #LungHealth #COPDAwareness

A new COVID treatment could be on the horizon as Christophe Demaison and the COPD Foundation begin phase 2 testing for their antiviral nasal spray to treat the coronavirus. #nasalspray #COVID19 loom.ly/aIfpb0M

The first participants have been successfully dosed in Christophe Demaison 's INNA-051 pan-antiviral Phase 2a flu-challenge study in collaboration with hVIVO. globenewswire.com/news-release/2…

We'll be at #ATS2022 this weekend! Join us on 5/14 at the Respiratory Innovation Summit for a company update and on 5/16 at 11:15am for our CMO, Dr. Scott White’s, poster presentation on Phase 1 INNA-051 data. Visit ATS2022 website to learn more: conference.thoracic.org

We’re the first Australian company selected for BLUE KNIGHT™, a Johnson & Johnson Innovation and BARDA initiative to help accelerate development for INNA-051, our pan-antiviral nasal spray. INNA-051 is designed to stimulate the innate immunity in the nose. globenewswire.com/news-release/2…

Wonderful to be at ⁦Johnson & Johnson Innovation⁩ ⁦JLABS⁩ in #DC supporting our first #Australian #BlueKnight company ⁦Christophe Demaison⁩ with Christophe Demaison. “The Power of Partnering to Accelerate Preparedness 2022 Symposium” with partners from ⁦BARDA⁩

Disease societies are working together with early-stage companies to transform the lives of patients. Watch live now as Jack Mahler (Cystic Fibrosis Foundation) & Ruth Tal-Singer (COPD Foundation) join @felixbiotech & Christophe Demaison at the #BLUEKNIGHT Symposia jji.jnj/bksymposium

Happening now- ⁦Johnson & Johnson Innovation⁩ ⁦JLABS #BlueKnight Christophe Demaison⁩ CEO Christophe Demaison sharing their experience of industry & disease foundation collaborations to accelerate drug development. Engaging disease communities to access patient & clinical insights ✅

It was an honor to participate in a panel discussion with Christophe Demaison on partnership between startups and patient advocacy groups jji.jnj/bksymposium #copd360net #copdfoundation